LENA BIOSCIENCES, INC. — Department of Health and Human Services SBIR Phase II: 100

Description

Organ on a chip tools that recapitulate human biologyphysiology and pathology are urgently needed in applied science research and drug testing to expedite discoveries while reducing research costs and animal sacrificeUnfortunatelymost products incorporating circulation mimicking perfusion are too complicated for researchers to useincompatible with many protocols and readsand low throughputOur goal is to change this for ordinary lab personnel and for researchers across disciplinesWe will make a researcher centric product that does not require special skills or training for usea tool that is flexible enough to serve diverse research objectivesand a tool that for pharmaceutical industry means a simplelow cost solution for predictive drug testingLena Biosciencesperfusedhumanmulti organ platform will revolutionize preclinical testing of first line therapy drugs that clear or metabolize slowlysaving pharmaceutical companies time and money while reducing human safety hazardsThe platform will be made in a standardscreening accessible format known to any user in life sciencesbiotechnology and drug discovery for ease of use and user adoptionIt will support perfusedthree dimensional organ models for physiologically closer drug delivery and distribution by mimicking drug distribution intra tissue and intra tissue resistance to drug transportIt will be especially well suited for in vitro testing of high molecular weighthumanized therapeutics that are administered to patients intravenously and retained in circulation for the period of weeksUltimatelythe platform will also serve as a prognostic tool by providing concentrated cell secretomeproteome and metabolome to prevent severe reactions in human trials while facilitating identification of biomarkerscellular and biochemical changes in response to drugsThe utility of this human platform will be demonstrated using three dimensional organ models of lung cancerbreast cancerbrain and liverand further validated by showing predictive in vitro efficacy and off target toxicity testing of approved drugs This perfusedhumanmulti organ research platform will enable disease fingerprinting and drug testing in vitroIt will advance public health by enabling fasterlow cost testing of drug candidates for the ultimate safe and effective treatment of cancerinflammatoryinfectiousautoimmuneneurological and cardiovascular diseases